Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
High Blood Pressure & Cardiovascular Prevention
Erschienen in: High Blood Pressure & Cardiovascular Prevention 1/2018

01.03.2018 | Review Article

Excess Body Weight, Insulin Resistance and Isolated Systolic Hypertension: Potential Pathophysiological Links

verfasst von: Lanfranco D’Elia, Pasquale Strazzullo

Erschienen in: High Blood Pressure & Cardiovascular Prevention | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

Isolated systolic hypertension, the most common form of hypertension in the elderly, but also detectable among young and middle-aged subjects, is independently associated with higher risk of cardiovascular events and all-cause mortality. Among various pathophysiological changes associated with aging, excess body weight and insulin resistance may predispose to this type of hypertension. Overweight or frank obesity and their frequent companion insulin resistance could mediate the development of isolated systolic hypertension through increase in the renin–angiotensin–aldosterone system activity, in the sympathetic tone and in salt-sensitivity, all in turn leading to endothelial dysfunction, arterial stiffness and increase in blood pressure. This review will focus on this cluster of pathophysiological factors and on the mechanistic pathways whereby they may favor the development of isolated systolic hypertension.
Literatur
1.
Yano Y, Lloyd-Jones DM. Isolated systolic hypertension in young and middle-aged adults. Curr Hypertens Rep. 2016;18:78.CrossRefPubMed
2.
Conen D, Bamberg F. Noninvasive 24-h ambulatory blood pressure and cardiovascular disease: a systematic review and meta-analysis. J Hypertens. 2008;26(7):1290–9.CrossRefPubMed
3.
Ekundayo OJ, Allman RM, Sanders PW, Aban I, Love TE, Arnett D, Ahmed A. Isolated systolic hypertension and incident heart failure in older adults: a propensity matched study. Hypertension. 2009;53(3):458–65.CrossRefPubMedPubMedCentral
4.
Li Y, Wei FF, Thijs L, Boggia J, Asayama K, Hansen TW, Kikuya M, Björklund-Bodegård K, Ohkubo T, Jeppesen J, Gu YM, Torp-Pedersen C, Dolan E, Liu YP, Kuznetsova T, Stolarz-Skrzypek K, Tikhonoff V, Malyutina S, Casiglia E, Nikitin Y, Lind L, Sandoya E, Kawecka-Jaszcz K, Mena L, Maestre GE, Filipovský J, Imai Y, O’Brien E, Wang JG, Staessen JA, International Database on Ambulatory Blood Pressure in Relation to Cardiovascular Outcomes (IDACO) Investigators. Ambulatory hypertension subtypes and 24-hour systolic and diastolic blood pressure as distinct outcome predictors in 8341 untreated people recruited from 12 populations. Circulation. 2014;130(6):466–74.CrossRefPubMedPubMedCentral
5.
Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, Chalmers J, Rodgers A, Rahimi K. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387(10022):957–67.CrossRefPubMed
6.
Yano Y, Stamler J, Garside DB, Daviglus ML, Franklin SS, Carnethon MR, Liu K, Greenland P, Lloyd-Jones DM. Isolated systolic hypertension in young and middle-aged adults and 31-year risk for cardiovascular mortality: the Chicago Heart Association Detection Project in Industry study. J Am Coll Cardiol. 2015;65:327–35.CrossRefPubMedPubMedCentral
7.
Franklin SS, Gustin W, Wong ND, Larson MG, Weber MA, Kannel WB, Levy D. Hemodynamic patterns of age-related changes in blood pressure The Framingham Heart Study. Circulation. 1997;96(1):308–15.CrossRefPubMed
8.
Chobanian AV. Clinical practice. Isolated systolic hypertension in the elderly. N Engl J Med. 2007;357(8):789–96.CrossRefPubMed
9.
Franklin SS. Elderly hypertensives: how are they different? J Clin Hypertens (Greenwich). 2012;14(11):779–86.CrossRef
10.
World Health Organization. Obesity: preventing and managing the global epidemic [WHO technical report series #894]. Geneva: World Health Organization; 2000.
11.
Adams KF, Schatzkin A, Harris TB, Kipnis V, Mouw T, Ballard-Barbash R, Hollenbeck A, Leitzmann MF. Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old. N Engl J Med. 2006;355:763–78.CrossRefPubMed
12.
Strazzullo P, D’Elia L, Cairella G, Garbagnati F, Cappuccio FP, Scalfi L. Excess body weight and incidence of stroke: meta-analysis of prospective studies with 2 million participants. Stroke. 2010;41(5):e418–26.CrossRefPubMed
13.
Aronne LJ, Brown WV, Isoldi KK. Cardiovascular disease in obesity: a review of related risk factors and risk reduction strategies. J Clin Lipidol. 2007;1:575–82.CrossRefPubMed
14.
Goldberg RB. Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications. J Clin Endocrinol Metab. 2009;94:3171–82.CrossRefPubMed
15.
Herder C, Haastert B, Muller-Scholze S, et al. Association of systemic chemokine concentrations with impaired glucose tolerance and type 2 diabetes: results from the Cooperative Health Research in the Region of Augsburg Survey S4 (KORA S4). Diabetes. 2005;54:S11–7.CrossRefPubMed
16.
Rimm EB, Stampfer MJ, Giovannucci E, Ascherio A, Spiegelman D, Colditz GA, Willett WC. Body size and fat distribution as predictors of coronary heart disease among middle-aged and older US men. Am J Epidemiol. 1995;141:1117–27.CrossRefPubMed
17.
Ryo M, Nakamura T, Kihara S, Kumada M, Shibazaki S, Takahashi M, Nagai M, Matsuzawa Y, Funahashi T. Adiponectin as a biomarker of the metabolic syndrome. Circ J. 2004;68:975–81.CrossRefPubMed
18.
Olefsky JM. The insulin receptor: its role in insulin resistance of obesity and diabetes. Diabetes. 1976;25:1154–62.CrossRefPubMed
19.
Caro JF, Sinha MK, Raju SM, Ittoop O, Pories WJ, Flickinger EG, Meelheim D, Dohm GL. Insulin receptor kinase in human skeletal muscle from obese subjects with and without noninsulin dependent diabetes. J Clin Investig. 1987;79:1330–7.CrossRefPubMedPubMedCentral
20.
Lyon CJ, Law RE, Hsueh WA. Minireview: adiposity, inflammation, and atherogenesis. Endocrinology. 2003;144:2195–200.CrossRefPubMed
21.
22.
Bender SB, McGraw AP, Jaffe IZ, Sowers JR. Mineralocorticoid receptor-mediated vascular insulin resistance: an early contributor to diabetes-related vascular disease? Diabetes. 2013;62:313–9.CrossRefPubMedPubMedCentral
23.
Kanda H, Tateya S, Tamori Y, Kotani K, Hiasa K, Kitazawa R. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Investig. 2006;116:1494–505.CrossRefPubMedPubMedCentral
24.
Amasyali B, Kose S, Kursaklioglu H, Kilic A, Isik E. Leptin in acute coronary syndromes: has the time come for its use in risk stratification? Int J Cardiol. 2008;130(2):264–5.CrossRefPubMed
25.
Carlyle M, Jones OB, Kuo JJ, Hall JE. Chronic cardiovascular and renal actions of leptin: role of adrenergic activity. Hypertension. 2002;39:496–501.CrossRefPubMed
26.
Galletti F, D’Elia L, Barba G, Siani A, Cappuccio FP, Farinaro E, Iacone R, Russo O, De Palma D, Ippolito R, Strazzullo P. High-circulating leptin levels are associated with greater risk of hypertension in men independently of body mass and insulin resistance: results of an eight-year follow-up study. J Clin Endocrinol Metab. 2008;93(10):3922–6.CrossRefPubMed
27.
Frayn KN. Obesity and metabolic disease: is adipose tissue the culprit? Proc Nutr Soc. 2005;64:7–13.CrossRefPubMed
28.
Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K, Kuriyama H, Nishida M, Yamashita S, Okubo K, Matsubara K, Muraguchi M, Ohmoto Y, Funahashi T, Matsuzawa Y. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun. 1999;257:79–83.CrossRefPubMed
29.
Doronzo G, Russo I, Mattiello L, Anfossi G, Bosia A, Trovati M. Insulin activates vascular endothelial growth factor in vascular smooth muscle cells: influence of nitric oxide and of insulin resistance. Eur J Clin Investig. 2004;34:664–73.CrossRef
30.
Torjesen AA, Sigurðsson S, Westenberg JJ, Gotal JD, Bell V, Aspelund T, Launer LJ, de Roos A, Gudnason V, Harris TB, Mitchell GF. Pulse pressure relation to aortic and left ventricular structure in the Age, Gene/Environment Susceptibility (AGES)-Reykjavik Study. Hypertension. 2014;64:756–61.CrossRefPubMedPubMedCentral
31.
DeMarco VG, Habibi J, Jia G, Aroor AR, Ramirez-Perez FI, Martinez-Lemus LA, Bender SB, Garro M, Hayden MR, Sun Z, Meininger GA, Manrique C, Whaley-Connell A, Sowers JR. Low-dose mineralocorticoid receptor blockade prevents western diet-induced arterial stiffening in female mice. Hypertension. 2015;66:99–107.CrossRefPubMedPubMedCentral
32.
Chung AW, Yang HH, Sigrist MK, Brin G, Chum E, Gourlay WA, Levin A. Matrix metalloproteinase-2 and -9 exacerbate arterial stiffening and angiogenes is in diabetes and chronic kidney disease. Cardiovasc Res. 2009;84:494–504.CrossRefPubMed
33.
Poirier P, Martin J, Marceau P, Biron S, Marceau S. Impact of bariatric surgery on cardiac structure, function and clinical manifestations in morbid obesity. Expert Rev Cardiovasc Ther. 2004;2:193–201.CrossRefPubMed
34.
Seifalian AM, Filippatos TD, Joshi J, Mikhailidis DP. Obesity and arterial compliance alterations. Curr Vasc Pharmacol. 2010;8(2):155–68.CrossRefPubMed
35.
Selcuk A, Bulucu F, Kalafat F, Cakar M, Demirbas S, Karaman M, Ay SA, Saglam K, Balta S, Demirkol S, Arslan E. Skinfold thickness as a predictor of arterial stiffness: obesity and fatness linked to higher stiffness measurements in hypertensive patients. Clin Exp Hypertens. 2013;35(6):459–64.CrossRefPubMed
36.
Creager MA, Luscher TF, Cosentino F, Beckman JA. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: PartI. Circulation. 2003;108:1527–32.CrossRefPubMed
37.
Gorzelniak K, Engeli S, Janke J, Luft FC, Sharma AM. Hormonal regulation of the human adipose-tissue renin–angiotensin system: relationship to obesity and hypertension. J Hypertens. 2002;20(5):965–73.CrossRefPubMed
38.
Cote AT, Harris KC, Panagiotopoulos C, Sandor GG, Devlin AM. Childhood obesity and cardiovascular dysfunction. J Am Coll Cardiol. 2013;62:1309–19.CrossRefPubMed
39.
Zucker IH. Novelmecha- nisms of sympathetic regulation in chronic heart failure. Hypertension. 2006;48:1005–11.CrossRefPubMed
40.
Taddei S, Virdis A, Mattei P, Favilla S, Salvetti A. Angiotensin II and sympathetic activity in sodium-restricted essential hypertension. Hypertension. 1995;25:595–601.CrossRefPubMed
41.
Reid IA. Interactions between ANG II, sympathetic nervous system, and baroreceptor reflexes in regulation of blood pressure. Am J Physiol. 1992;262:E763–78.PubMed
42.
Clasen R, Schupp M, Foryst-Ludwig A, Sprang C, Clemenz M, Krikov M, ThÖne-Reineke C, Unger T, Kintscher U. PPARgamma- activating angiotensin type-1 receptor blockers induce adiponectin. Hypertension. 2005;46(1):137–43.CrossRefPubMed
43.
Mahmud A, Feely J. Arterial stiffness and the renin–angiotensin–aldosterone system. J Renin Angiotensin Aldosterone Syst. 2004;5(3):102–8.CrossRefPubMed
44.
Rompe F, Artuc M, Hallberg A, Alterman M, Ströder K, Thöne-Reineke C, Reichenbach A, Schacherl J, Dahlöf B, Bader M, Alenina N, Schwaninger M, Zuberbier T, Funke-Kaiser H, Schmidt C, Schunck WH, Unger T, Steckelings UM. Direct angiotensin II type 2 receptor stimulation acts anti-inflammatory through epoxyeicosatrienoic acid and inhibition of nuclear factor kappaB. Hypertension. 2010;55(4):924–31.CrossRefPubMed
45.
Wallin BG, Charkoudian N. Sympathetic neural control of integrated cardiovascular function: insights from measurement of human sympathetic nerve activity. Muscle Nerve. 2007;36:595–614.CrossRefPubMed
46.
Katovich MJ, Pachori A. Effects of inhibition of the renin–angiotensin system on the cardiovascular actions of insulin. Diabetes Obes Metab. 2000;2(1):3–14.CrossRefPubMed
47.
Grassi G, Dell’Oro R, Facchini A, Quarti Trevano F, Bolla GB, Mancia G. Effect of central and peripheral body fat distribution on sympathetic and baroreflex function in obese normotensives. J Hypertens. 2004;22:2363–9.CrossRefPubMed
48.
Patel KP, Li YF, Hirooka Y. Role of nitric oxide in central sympathetic outflow. Exp Biol Med (Maywood). 2001;226:814–24.CrossRefPubMed
49.
Bruijns RH, VanKleef EM, Smits JF, DeMey JG, Daemen MJ. Effects of chemical sympathectomy on angiotensin II-induced neo intimal growth in the balloon-injured rat carotid artery. J Vasc Res. 1998;35:124–33.CrossRefPubMed
50.
Swierblewska E, Hering D, Kara T, Kunicka K, Kruszewski P, Bieniaszewski L, Boutouyrie P, Somers VK, Narkiewicz K. An independent relationship between muscle sympathetic nerve activity and pulse wave velocity in normal humans. J Hypertens. 2010;28(5):979–84.CrossRefPubMed
51.
Boutouyrie P, Lacolley P, Girerd X, Beck L, Safar M, Laurent S. Sympathetic activation decreases radial artery compliance in humans. Am J Physiol. 1994;267:H1368–76.PubMed
52.
Mangoni AA, Mircoli L, Giannattasio C, Mancia G, Ferrari AU. Effects of sympathectomy on mechanical properties of common carotid and femoral arteries. Hypertension. 1997;30:1085–8.CrossRefPubMed
53.
Failla M, Grappiolo A, Emanuelli G, Vitale G, Fraschini N, Giannattasio C, Mancia G. Sympathetic tone restrains arterial distensibility of healthy and atherosclerotic subjects. J Hypertens. 1999;17:1117–24.CrossRefPubMed
54.
World Health Organization. Reducing salt intake in populations: report of a WHO forum and technical meeting. Geneva: WHO; 2007. p. 1–60.
55.
Donfrancesco C, Ippolito R, Lo Noce C, Palmieri L, Iacone R, Russo O, Vanuzzo D, Galletti F, Galeone D, Giampaoli S, Strazzullo P. Excess dietary sodium and inadequate potassium intake in Italy: results of the MINISAL study. Nutr Metab Cardiovasc Dis. 2013;23:850–6.CrossRefPubMed
56.
He FJ, Markandu ND, MacGregor GA. Modest salt reduction lowers blood pressure in isolated systolic hypertension and combined hypertension. Hypertension. 2005;46(1):66–70.CrossRefPubMed
57.
Pimenta E, Gaddam KK, Oparil S, Aban I, Husain S, Dell’Italia LJ, Calhoun DA. Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial. Hypertension. 2009;54:475–81.CrossRefPubMedPubMedCentral
58.
He FJ, Li J, Macgregor GA. Effect of longer term modest salt reduction on blood pressure: Cochrane systematic review and meta-analysis of randomized trials. BMJ. 2013;346:f1325.CrossRefPubMed
59.
Strazzullo P, Galletti F, Dessì-Fulgheri P, Ferri C, Glorioso N, Malatino L, Mantero F, Manunta P, Semplicini A, Ghiadoni L, Zoccali C. Prediction and consistency of blood pressure salt-sensitivity as assessed by a rapid volume expansion and contraction protocol. Salt-Sensitivity Study Group of the Italian Society of Hypertension. J Nephrol. 2000;13:46–53.PubMed
60.
Strazzullo P, Galletti F, Barba G. Altered renal handling of sodium in human hypertension: short review of the evidence. Hypertension. 2003;41:1000–5.CrossRefPubMed
61.
Galletti F, Strazzullo P, Ferrara I, Annuzzi G, Rivellese AA, Gatto S, Mancini M. NaCl sensitivity of essential hypertensive patients is related to insulin resistance. J Hypertens. 1997;15:1485–91.CrossRefPubMed
62.
Rocchini AP, Key J, Bondie D, Chico R, Moorehead C, Katch V, Martin M. The effect of weight loss on the sensitivity of blood pressure to sodium in obese adolescents. N Engl J Med. 1989;321:580–5.CrossRefPubMed
63.
Strazzullo P, Barbato A, Galletti F, Barba G, Siani A, Iacone R, D’Elia L, Russo O, Versiero M, Farinaro E, Cappuccio FP. Abnormalities of renal sodium handling in the metabolic syndrome. Results of the Olivetti Heart Study. J Hypertens. 2006;24:1633–9.CrossRefPubMed
64.
Chen J, Gu D, Huang J, Rao DC, Jaquish CE, Hixson JE, Chen CS, Chen J, Lu F, Hu D, Rice T, Kelly TN, Hamm LL, Whelton PK, He J, GenSalt Collaborative Research Group. Metabolic syndrome and salt sensitivity of blood pressure in non-diabetic people in China: a dietary intervention study. Lancet. 2009;373:829–35.CrossRefPubMedPubMedCentral
65.
Strazzullo P, Barba G, Cappuccio FP, Siani A, Trevisan M, Farinaro E, Pagano E, Barbato A, Iacone R, Galletti F. Altered renal sodium handling in men with abdominal adiposity: a link to hypertension. J Hypertens. 2001;19:2157–64.CrossRefPubMed
66.
Barbato A, Cappuccio FP, Folkerd EJ, Strazzullo P, Sampson B, Cook DG, Alberti KG. Metabolic syndrome and renal sodium handling in three ethnic groups living in England. Diabetologia. 2004;47:40–6.CrossRefPubMed
67.
Barba G, Russo O, Siani A, Iacone R, Farinaro E, Gerardi MC, Russo P, Della Valle E, Strazzullo P. Plasma leptin and blood pressure in men: graded association independent of body mass and fat pattern. Obes Res. 2003;11:160–6.CrossRefPubMed
68.
Bragulat E, de la Sierra A, Antonio MT, Coca A. Endothelial dysfunction in salt-sensitive essential hypertension. Hypertension. 2001;37:444–8.CrossRefPubMed
69.
Avolio AP, Deng FQ, Li WQ, Luo YF, Huang ZD, Xing LF, O’Rourke MF. Effects of aging on arterial distensibility in populations with high and low prevalence of hypertension: comparison between urban and rural communities in China. Circulation. 1985;71:202–10.CrossRefPubMed
70.
Avolio AP, Clyde KM, Beard TC, Cooke HM, Ho KK, O’Rourke MF. Improved arterial distensibility in normotensive subjects on a low salt diet. Arteriosclerosis. 1986;6:166–9.CrossRefPubMed
71.
Nickenig G, Strehlow K, Roeling J, Zolk O, Knorr A, Böhm M. Salt induces vascular AT1 receptor overexpression in vitro and in vivo. Hypertension. 1998;31:1272–7.CrossRefPubMed
72.
73.
Ying W-Z, Sanders PW. Dietary salt increases endothelial nitric oxide synthase and TGF-β1 in rat aortic endothelium. Am J Physiol. 1999;277(4 Pt 2):H1293–8.PubMed
74.
Ying W-Z, Sanders PW. Dietary salt modulates renal production of transforming growth factor-β in rats. Am J Physiol. 1998;274(4 Pt 2):F635–41.PubMed
75.
Matavelli LC, Zhou X, Varagic J, Susic D, Frohlich ED. Salt loading produces severe renal hemodynamic dysfunction independent of arterial pressure in spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol. 2007;292:H814–9.CrossRefPubMed
76.
Kocks MJ, Buikema H, Gschwend S, Boomsma F, de Zeeuw D, Navis G. High dietary sodium blunts affects of angiotensin-converting enzyme inhibition on vascular angiotensin I-to-angiotensin II conversion in rats. J Cardiovasc Pharmacol. 2003;42:601–6.CrossRefPubMed
77.
Matsuoka H, Itoh S, Kimoto M, Kohno K, Tamai O, Wada Y, Yasukawa H, Iwami G, Okuda S, Imaizumi T. Asymmetrical dimethylarginine, an endogenous nitric oxide synthase inhibitor, in experimental hypertension. Hypertension. 1997;29(1 Pt 2):242–7.CrossRefPubMed
78.
Ni Z, Vaziri ND. Effect of salt loading on nitric oxide synthase expression in normotensive rats. Am J Hypertens. 2001;14(2):155–63.CrossRefPubMed
79.
Oberleithner H, Peters W, Kusche-Vihrog K, Korte S, Schillers H, Kliche K, Oberleithner K. Salt overload damages the glycocalyx sodium barrier of vascular endothelium. Pflugers Arch. 2011;462(4):519–28.CrossRefPubMedPubMedCentral
80.
Leenen FH, Ruzicka M, Huang BS. The brain and salt-sensitive hypertension. Curr Hypertens Rep. 2002;4:129–35.CrossRefPubMed
81.
King AJ, Novotny M, Swain GM, Fink GD. Whole body norepinephrine kinetics in ANG II-salt hypertension in the rat. Am J Physiol Regul Integr Comp Physiol. 2008;294:R1262–7.CrossRefPubMed
82.
Jacob F, Clark LA, Guzman PA, Osborn JW. Role of renal nerves in development of hypertension in DOCA-salt model in rats: a telemetric approach. Am J Physiol Heart Circ Physiol. 2005;289:H1519–29.CrossRefPubMed
83.
King AJ, Osborn JW, Fink GD. Splanchnic circulation is a critical neural target in angiotensin II salt hypertension in rats. Hypertension. 2007;50:547–56.CrossRefPubMed
84.
Stocker SD, Madden CJ, Sved AF. Excess dietary salt intake alters the excitability of central sympathetic networks. Physiol Behav. 2010;100(5):519–24.CrossRefPubMedPubMedCentral
85.
Ciura S, Bourque CW. Transient receptor potential vanilloid 1 is required for intrinsic osmoreception in organum vasculosum lamina terminalis neurons and for normal thirst responses to systemic hyperosmolality. J Neurosci. 2006;26(35):9069–75.CrossRefPubMed
86.
Brooks VL, Freeman KL, O’Donaughy TL. Acute and chronic increases in osmolality increase excitatory amino acid drive of the rostral ventrolateral medulla in rats. Am J Physiol Regul Integr Comp Physiol. 2004;287(6):R1359–68.CrossRefPubMed
87.
Weiss ML, Claassen DE, Hirai T, Kenney MJ. Nonuniform sympathetic nerve responses to intravenous hypertonic saline infusion. J Auton Nerv Syst. 1996;57(1–2):109–15.CrossRefPubMed
88.
Farquhar WB, Paul EE, Prettyman AV, Stillabower ME. Blood pressure and hemodynamic responses to an acute sodium load in humans. J Appl Physiol. 2005;99(4):1545–51.CrossRefPubMed
89.
Farquhar WB, Wenner MM, Delaney EP, Prettyman AV, Stillabower ME. Sympathetic neural responses to increased osmolality in humans. Am J Physiol Heart Circ Physiol. 2006;291(5):H2181–6.CrossRefPubMed
90.
Peskind ER, Radant A, Dobie DJ, Hughes J, Wilkinson CW, Sikkema C, Veith RC, Dorsa DM, Raskind MA. Hypertonic saline infusion increases plasma norepinephrine concentrations in normal men. Psychoneuroendocrinology. 1993;18(2):103–13.CrossRefPubMed
91.
Strazzullo P, D’Elia L, Kandala NB, Cappuccio FP. Salt intake, stroke, and cardiovascular disease: meta-analysis of prospective studies. BMJ. 2009;24(339):b4567.CrossRef
Metadaten
Titel
Excess Body Weight, Insulin Resistance and Isolated Systolic Hypertension: Potential Pathophysiological Links
verfasst von
Lanfranco D’Elia
Pasquale Strazzullo
Publikationsdatum
01.03.2018
Verlag
Springer International Publishing
Erschienen in
High Blood Pressure & Cardiovascular Prevention / Ausgabe 1/2018
Print ISSN: 1120-9879
Elektronische ISSN: 1179-1985
DOI
https://doi.org/10.1007/s40292-017-0240-1

Weitere Artikel der Ausgabe 1/2018

High Blood Pressure & Cardiovascular Prevention 1/2018 Zur Ausgabe

Original Article

Cardiac Biomarkers Release in Preadolescent Athletes After an High Intensity Exercise

Original Article

Anticoagulant Therapy in Atrial Fibrillation for Stroke Prevention: Assessment of Agreement Between Clinicians’ Decision and CHA2DS2-VASc and HAS-BLED Scores

Commentary

Commentary to: “The Effects of Coenzyme Q10 Supplementation on Blood Pressures Among Patients with Metabolic Diseases: A Systematic Review and Meta-analysis of Randomized Controlled Trials”

Original Article

Perception, Knowledge, and Attitude toward Physical Activity Behaviour: Implications for Participation among Individuals with Essential Hypertension

Editorial

Proprotein Convertase Subtilisin-Kexin Type 9 (PCSK9) Inhibitors and Cardiovascular Risk: Does a Further Analysis of the Fourier Trial Suggest Changes in the Target of Lipid Lowering Therapy?

Editorial

Calcium Channel Blockers for the Clinical Management of Hypertension

Neu im Fachgebiet Kardiologie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

21.05.2024 TAVI Nachrichten

Bei schwerer Aortenstenose und obstruktiver KHK empfehlen die Leitlinien derzeit eine chirurgische Kombi-Behandlung aus Klappenersatz plus Bypass-OP. Diese Empfehlung wird allerdings jetzt durch eine aktuelle Studie infrage gestellt – mit überraschender Deutlichkeit.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen